110,215 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Rheos Capital Works Inc.

Rheos Capital Works Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGLFree Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 110,215 shares of the biopharmaceutical company’s stock, valued at approximately $29,432,000. Madrigal Pharmaceuticals comprises approximately 1.4% of Rheos Capital Works Inc.’s holdings, making the stock its 19th biggest holding. Rheos Capital Works Inc. owned about 0.55% of Madrigal Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of MDGL. Paulson & CO. Inc. lifted its stake in Madrigal Pharmaceuticals by 121.1% during the 4th quarter. Paulson & CO. Inc. now owns 1,105,741 shares of the biopharmaceutical company’s stock worth $255,846,000 after acquiring an additional 605,741 shares in the last quarter. RTW Investments LP lifted its position in shares of Madrigal Pharmaceuticals by 163.4% during the fourth quarter. RTW Investments LP now owns 815,191 shares of the biopharmaceutical company’s stock worth $188,619,000 after purchasing an additional 505,706 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Madrigal Pharmaceuticals by 21.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 1,888,888 shares of the biopharmaceutical company’s stock valued at $437,051,000 after purchasing an additional 333,888 shares during the period. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at approximately $75,110,000. Finally, AlpInvest Partners B.V. acquired a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at approximately $48,934,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Stock Up 4.0 %

Shares of NASDAQ:MDGL traded up $10.63 during midday trading on Friday, reaching $278.42. The company had a trading volume of 586,651 shares, compared to its average volume of 558,754. The stock has a market capitalization of $5.93 billion, a P/E ratio of -12.06 and a beta of -0.41. The stock’s fifty day moving average price is $232.85 and its 200-day moving average price is $234.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.39 and a quick ratio of 9.39. Madrigal Pharmaceuticals, Inc. has a one year low of $119.76 and a one year high of $299.98.

Madrigal Pharmaceuticals (NASDAQ:MDGLGet Free Report) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($7.38) EPS for the quarter, missing analysts’ consensus estimates of ($6.06) by ($1.32). During the same period in the prior year, the company earned ($4.23) earnings per share. Equities research analysts expect that Madrigal Pharmaceuticals, Inc. will post -27.62 earnings per share for the current fiscal year.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, VP Robert E. Waltermire sold 1,036 shares of Madrigal Pharmaceuticals stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $231.34, for a total transaction of $239,668.24. Following the sale, the vice president now owns 5,500 shares of the company’s stock, valued at approximately $1,272,370. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Robert E. Waltermire sold 1,036 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $231.34, for a total transaction of $239,668.24. Following the transaction, the vice president now owns 5,500 shares in the company, valued at $1,272,370. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Rebecca Taub sold 27,506 shares of the business’s stock in a transaction on Friday, April 5th. The stock was sold at an average price of $243.36, for a total value of $6,693,860.16. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares in the company, valued at approximately $111,701,996.64. The disclosure for this sale can be found here. Insiders have sold a total of 173,921 shares of company stock worth $37,491,547 in the last ninety days. 23.92% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MDGL. Canaccord Genuity Group increased their price target on Madrigal Pharmaceuticals from $338.00 to $377.00 and gave the company a “buy” rating in a research report on Friday, March 15th. TD Cowen lifted their price target on shares of Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the stock an “outperform” rating in a research note on Friday, March 15th. Evercore ISI increased their price objective on shares of Madrigal Pharmaceuticals from $325.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, March 20th. Piper Sandler restated an “overweight” rating and issued a $336.00 price objective on shares of Madrigal Pharmaceuticals in a report on Thursday, March 14th. Finally, HC Wainwright lowered their target price on shares of Madrigal Pharmaceuticals from $425.00 to $390.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $348.17.

Read Our Latest Research Report on MDGL

Madrigal Pharmaceuticals Profile

(Free Report)

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

See Also

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.